Search

Search results

545 results found

Jennifer A. Tran, MD

Dr. Jennifer A. Tran graduated magna cum laude from Boston University with Honors as a Thomas M. Menino Scholar with her BA in Biology. As an undergraduate, she completed her thesis project on age-dependent neurodegeneration in the Drosophila brain, which led to a publication in the Journal of...

Inas F. Aboobakar, MD

Profiles Harvard Catalist Profile Mass Eye and Ear (clinical) Mass Eye and Ear (research)

Leyla Karim, OD

Profiles Boston Children's Hospital Profile Harvard Catalyst Profile

Message from the Editor-in-Chief

Dear Colleagues, In this issue of eye Insights, we take a close look at posterior uveitis. Inside, you’ll find techniques and tips for evaluating and managing patients with this condition. Due to its many etiologies, posterior uveitis can be challenging to treat until the cause of the inflammation...

Diagnosis

The most common symptoms of posterior uveitis are blurred vision and floaters, and the most common signs are chorioretinal infiltrates and vitreous cells. Posterior uveitis is diagnosed by slit lamp examination and indirect ophthalmoscopy. Imaging modalities, including fundus autofluorescence...

eye Insights 14: Genetic Therapies for Inherited Retinal Disorders

While gene therapy is not yet widely available for inherited retinal disorsers (IRDs), researchers are making exciting discoveries, and the future looks more promising than ever before. In this issue of eye Insights, we provide a look into current offerings in gene therapy, and a glimpse into the...

IRDs and Genetic Testing

Inherited retinal disorders are rare, hereditary disorders caused by mutations in genes that encode proteins needed for normal retinal health and function. The first gene associated with retinitis pigmentosa was identified at Mass Eye and Ear in 1990, and since then, over 250 IRD-causing genes have...

Current Gene Therapies for IRDs

The first gene-augmentation therapy for an IRD was approved by the U.S. Food and Drug Administration (FDA) in December 2017 after nearly two decades of development in preclinical models and clinical trials. The drug, known as Luxturna®, is for individuals with autosomal recessive retinal dystrophies...

Deborah VanderVeen, MD, Inducted into the American Ophthalmological Society

Deborah K. VanderVeen, MD, Associate Professor of Ophthalmology at Harvard Medical School and a clinician scientist at Boston Children's Hospital, has been elected to the prestigious American Ophthalmological Society for her distinguished contributions to the field, particularly her work in...

Paulo Bispo, PhD, Awarded ARVO Foundation Fellowship

Paulo Bispo, PhD, Assistant Professor of Ophthalmology at Harvard Medical School and Assistant Scientist at Mass Eye and Ear, received the 2022 Association for Research in Vision and Ophthalmology (ARVO) Mallinckrodt Uveitis Research Fellowship. This $45,000 fellowship award will fund Dr. Bispo's...